/CNW/ - Novo Nordisk announced today that Health Canada has approved a new indication for REBINYN® (Coagulation Factor IX (Recombinant), pegylated) for the.
Novo Nordisk (NVO) said on July 29 that its once-weekly insulin icodec showed superior reduction in blood glucose levels versus its own medicine Tresiba (insulin degludec) and was seen.
My previous analysis on Novo Nordisk a few months back showed the company as overvalued and a HOLD. Following 5% drop in today's market, I still rate NVO stock as a hold. Click to know.